Altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism
- PMID: 16554448
- PMCID: PMC4196422
- DOI: 10.1177/0091270006286434
Altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism
Abstract
This study investigated the potential differences in methylprednisolone pharmacodynamics between healthy subjects with different histamine N-methyltransferase (HNMT) C314T genotypes. Six individuals with C/C genotype and 4 with C/T genotype were administered a single intravenous dose of methylprednisolone 0.6 mg/kg ideal body weight in a randomized 2-period manner. Methylprednisolone plasma concentrations were fitted with a 1-compartment model. Cortisol and whole blood histamine suppression were assessed by indirect response models, with circadian baseline cortisol analyzed by Fourier analysis. The area between the baseline and effect curve and the area under the effect versus time curve suppression ratio were used to characterize plasma histamine suppression. Methylprednisolone pharmacokinetics and plasma and whole blood histamine suppression were similar between the 2 genotype groups. Median nadir of cortisol and the 50% inhibitory concentration for cortisol were significantly higher in subjects with C/T genotype than those with C/C genotype (P=.031 and .033, respectively, Wilcoxon rank sum test). Subjects who are heterozygous for the T314 variant allele thus appeared less sensitive to the suppressive effects of methylprednisolone on cortisol secretion.
Figures





Similar articles
-
Endogenous histamine and cortisol levels in subjects with different histamine N-methyltransferase C314T genotypes : a pilot study.Mol Diagn Ther. 2006;10(2):109-14. doi: 10.1007/BF03256450. Mol Diagn Ther. 2006. PMID: 16669609 Free PMC article.
-
Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics.Clin Pharmacol Ther. 1996 Mar;59(3):312-21. doi: 10.1016/S0009-9236(96)80009-9. Clin Pharmacol Ther. 1996. PMID: 8653994 Clinical Trial.
-
Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm.Clin Pharmacol Ther. 1992 Jun;51(6):677-88. doi: 10.1038/clpt.1992.80. Clin Pharmacol Ther. 1992. PMID: 1535301 Free PMC article. Clinical Trial.
-
[Problems of equivalency points during therapy with glucocorticoids. A comparison of the clinical pharmacokinetics and pharmacodynamics of prednisolone and methylprednisolone].Dtsch Med Wochenschr. 1994 Dec 2;119(48):1671-6. doi: 10.1055/s-2008-1058886. Dtsch Med Wochenschr. 1994. PMID: 7988369 Review. German. No abstract available.
-
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003. Clin Pharmacokinet. 2005. PMID: 15634032 Review.
Cited by
-
Corticosteroid therapy in acute respiratory distress syndrome.CMAJ. 2013 Feb 19;185(3):216-21. doi: 10.1503/cmaj.120582. Epub 2012 Nov 12. CMAJ. 2013. PMID: 23148060 Free PMC article. Review. No abstract available.
-
Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.J Clin Pharmacol. 2006 May;46(5):515-26. doi: 10.1177/0091270006287588. J Clin Pharmacol. 2006. PMID: 16638735 Free PMC article.
-
Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variability.Pharm Res. 2007 Jun;24(6):1088-97. doi: 10.1007/s11095-006-9232-x. Epub 2007 Mar 24. Pharm Res. 2007. PMID: 17385022 Free PMC article. Clinical Trial.
-
Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone in Neonates Undergoing Cardiopulmonary Bypass.CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):913-922. doi: 10.1002/psp4.12470. Epub 2019 Oct 23. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31646767 Free PMC article. Clinical Trial.
References
-
- Maslinski C. Histamine and its metabolism in mammals, I: chemistry and formation of histamine. Agents Actions. 1975;5:89–107. - PubMed
-
- Maslinski C. Histamine and its metabolism in mammals, II: catabolism of histamine and histamine liberation. Agents Actions. 1975;5:183–225. - PubMed
-
- Okinaga S, Ohrui T, Nakazawa H, et al. The role of HMT (histamine N-methyltransferase) in airways: a review. Methods Find Exp Clin Pharmacol. 1995;17(suppl C):16–20. - PubMed
-
- Schayer RW, Reilly MA. Formation and fate of histamine in rat and mouse brain. J Pharmacol Exp Ther. 1973;184:33–40. - PubMed
-
- Schwartz JC, Pollard H, Bischoff S, et al. Catabolism of 3 H-histamine in the rat brain after intracisternal administration. Eur J Pharmacol. 1971;16:326–335. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical